Dr. Gunes has over a decade of experience in leading commercialization and product development at various 3M Business Units, including 3M Corporate R&D. The annual sales of the products that Dr. Gunes developed and commercialized well exceeds $100M. An engineer by training, he is in the process of completing his MBA at MIT Sloan, with cross training at Harvard Business School. Dr. Gunes is the inventor of 21 US patent applications and their foreign equivalents.
Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has a platform nano lipid particle technology that can be used in vaccine development.
